Ocular Therapeutix (OCUL)
(Real Time Quote from BATS)
$8.89 USD
+0.18 (2.07%)
Updated Sep 13, 2024 09:46 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
OCUL 8.89 +0.18(2.07%)
Will OCUL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OCUL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OCUL
Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
OCUL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Other News for OCUL
Opaleye Management Inc. Increases Stake in Eton Pharmaceuticals Inc.
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc.
Ocular Therapeutix? Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc.
Ocular Therapeutix? to Present at September Retina Meetings